Literature DB >> 15140962

Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker.

Tim Beaumont1, Esther Quakkelaar, Ad van Nuenen, Ralph Pantophlet, Hanneke Schuitemaker.   

Abstract

We previously described the adaptation of the neutralization-sensitive human immunodeficiency virus type 1 (HIV-1) strain IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker. During long-term propagation of this resistant isolate, designated FF3346, on primary peripheral blood leukocytes in vitro, an HIV-1 variant appeared that had regained sensitivity to neutralization by soluble CD4 (sCD4) and the broadly neutralizing monoclonal antibody b12. When an early passage of FF3346 was subjected to limiting-dilution culture in peripheral blood mononuclear cells, eight virus variants with various degrees of neutralization resistance were isolated. Two of them, the sCD4 neutralization-resistant variant LW_H8(res) and the sCD4 neutralization-sensitive variant LW_G9(sens), were selected for further study. Interestingly, these two viruses were equally resistant to neutralization by agents that recognize domains other than the CD4 binding site. Site-directed mutagenesis revealed that the increased neutralization sensitivity of variant LW_G9(sens) resulted from only two changes, an Asn-to-Ser substitution at position 164 in the V2 loop and an Ala-to-Glu substitution at position 370 in the C3 domain of gp120. In agreement with this notion, the affinity of b12 for monomeric gp120 containing the N164S and A370E substitutions in the background of the molecular clone LW_H8(res) was higher than its affinity for the parental gp120. Surprisingly, no correlation was observed between CD4 binding affinity for monomeric gp120 and the level of neutralization resistance, suggesting that differences in sCD4 neutralization sensitivity between these viruses are only manifested in the context of the tertiary or quaternary structure of gp120 on the viral surface. The results obtained here indicate that the neutralization-sensitive strain IIIB can become neutralization resistant in vivo under selective pressure by neutralizing antibodies but that this resistance may be easily reversed in the absence of immunological pressure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15140962      PMCID: PMC415840          DOI: 10.1128/JVI.78.11.5651-5657.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.

Authors:  U Olshevsky; E Helseth; C Furman; J Li; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

2.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.

Authors:  J P Moore; J A McKeating; Y X Huang; A Ashkenazi; D D Ho
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI.

Authors:  K Peden; M Emerman; L Montagnier
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

4.  Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.

Authors:  C Cheng-Mayer; A Brown; J Harouse; P A Luciw; A J Mayer
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.

Authors:  M R Posner; T Hideshima; T Cannon; M Mukherjee; K H Mayer; R A Byrn
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

6.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.

Authors:  M Thali; U Olshevsky; C Furman; D Gabuzda; M Posner; J Sodroski
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

7.  Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein.

Authors:  M Thali; C Furman; D D Ho; J Robinson; S Tilley; A Pinter; J Sodroski
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

8.  Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity.

Authors:  M Thali; U Olshevsky; C Furman; D Gabuzda; J Li; J Sodroski
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

9.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

10.  Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120.

Authors:  S Turner; R Tizard; J DeMarinis; R B Pepinsky; J Zullo; R Schooley; R Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

View more
  13 in total

1.  Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry.

Authors:  Eric G Meissner; Vernon M Coffield; Lishan Su
Journal:  Virology       Date:  2005-06-05       Impact factor: 3.616

2.  Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.

Authors:  Peter Rusert; Herbert Kuster; Beda Joos; Benjamin Misselwitz; Cornelia Gujer; Christine Leemann; Marek Fischer; Gabriela Stiegler; Hermann Katinger; William C Olson; Rainer Weber; Leonardo Aceto; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies.

Authors:  Marit J van Gils; Evelien M Bunnik; Brigitte D Boeser-Nunnink; Judith A Burger; Marijke Terlouw-Klein; Naomi Verwer; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

4.  Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.

Authors:  Evelien M Bunnik; Esther D Quakkelaar; Ad C van Nuenen; Brigitte Boeser-Nunnink; Hanneke Schuitemaker
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

5.  Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.

Authors:  Xueling Wu; Tongqing Zhou; Sijy O'Dell; Richard T Wyatt; Peter D Kwong; John R Mascola
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

6.  Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection.

Authors:  Evelien M Bunnik; Linaida Pisas; Ad C van Nuenen; Hanneke Schuitemaker
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

7.  Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors.

Authors:  Marit J van Gils; Evelien M Bunnik; Judith A Burger; Yodit Jacob; Becky Schweighardt; Terri Wrin; Hanneke Schuitemaker
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

8.  Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model.

Authors:  William L Ince; Liguo Zhang; Qi Jiang; Kathryn Arrildt; Lishan Su; Ronald Swanstrom
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

9.  The heptad repeat 2 domain is a major determinant for enhanced human immunodeficiency virus type 1 (HIV-1) fusion and pathogenicity of a highly pathogenic HIV-1 Env.

Authors:  Vijay Sivaraman; Liguo Zhang; Eric G Meissner; Jerry L Jeffrey; Lishan Su
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

10.  Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Authors:  James M Binley; Terri Wrin; Bette Korber; Michael B Zwick; Meng Wang; Colombe Chappey; Gabriela Stiegler; Renate Kunert; Susan Zolla-Pazner; Hermann Katinger; Christos J Petropoulos; Dennis R Burton
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.